Please login to the form below

Not currently logged in
Email:
Password:

Tonix appoints head of clinical development

Donald Kellerman has experience at Allergan, Map, Inspire and Glaxo Wellcome

Tonix Pharmaceuticals has appointed Dr Donald Kellerman to head the strategy and execution of its clinical programmes.

Dr Kellerman brings 30 years of industry experience to his new role as senior VP, clinical development and regulatory affairs.

This includes his most recent role as VP, scientific affairs for Allergan's inhalation products business. He took on this role after his previous company, Map Pharmaceuticals, was taken over by Allergan in 2013.

At Map, Dr Kellerman served as senior VP, clinical development and medical affairs at Map Pharmaceuticals having joined the company in 2008 from Inspire Pharmaceuticals.

He also has experience at GlaxoWellcome as director of respiratory clinical research.

3rd April 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics